CAMBRIDGE, Mass. & MONTREAL / Feb 29, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows.
TD Cowen 44th Annual Healthcare Conference
Panel Discussion: Gynecological Cancers
Date: Tuesday, March 5, 2024
Time: 10:30 a.m. Eastern Time
Location: Boston, MA
Bloom Burton 2024 Healthcare Investor Conference
Company Overview
Date: Tuesday, April 16, 2024
Time: 3:30 p.m. Eastern Time
Location: Toronto, ON
A live webcast of the TD Cowen corporate panel discussion and Bloom Burton company overview can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for at least 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
| Last Trade: | US$1.36 |
| Daily Change: | -0.03 -1.81 |
| Daily Volume: | 11,392 |
| Market Cap: | US$57.600M |
May 13, 2025 May 01, 2025 April 25, 2025 March 31, 2025 March 03, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
